Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application

[at noodls] – BERKELEY, CA — (Marketwire) — 02/25/13 — Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration … more

View todays social media effects on DVAX

View the latest stocks trending across Twitter. Click to view dashboard

See who Dynavax is hiring next, click here to view